Abivax (NASDAQ:ABVX) Announces Earnings Results

Abivax (NASDAQ:ABVX) issued its earnings results on Monday. The company reported ($1.24) EPS for the quarter, beating the consensus estimate of ($2.24) by $1.00, reports. The business had revenue of $1.47 million for the quarter, compared to the consensus estimate of $1.80 million.

Abivax Trading Down 4.1%

Shares of ABVX stock traded down $4.92 on Monday, hitting $115.42. The stock had a trading volume of 1,285,877 shares, compared to its average volume of 1,205,652. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. Abivax has a twelve month low of $4.77 and a twelve month high of $148.83. The company has a fifty day moving average price of $119.35 and a two-hundred day moving average price of $110.56. The firm has a market cap of $9.14 billion, a P/E ratio of -27.61 and a beta of 1.01.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Citigroup restated a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Wedbush started coverage on Abivax in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 target price on the stock. Guggenheim restated a “buy” rating and set a $175.00 target price on shares of Abivax in a report on Thursday, December 18th. Piper Sandler restated an “overweight” rating and set a $142.00 target price on shares of Abivax in a research report on Tuesday, December 16th. Finally, Jefferies Financial Group assumed coverage on Abivax in a research note on Monday, March 16th. They issued a “buy” rating and a $160.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Abivax currently has an average rating of “Moderate Buy” and a consensus target price of $136.69.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ABVX. Bank of America Corp DE lifted its holdings in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Abivax by 661.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after buying an additional 344 shares in the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in Abivax in the 4th quarter valued at approximately $61,000. Cubist Systematic Strategies LLC raised its position in Abivax by 34.3% in the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after buying an additional 2,595 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Abivax in the 2nd quarter valued at approximately $139,000. 47.91% of the stock is currently owned by institutional investors.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.